Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Melanotan 2 vs PT-141: Comparing Melanocortin Research Compounds (UK 2026)

Melanotan 2 vs PT-141: Comparing Melanocortin Research Compounds (UK 2026) Melanotan 2 (MT-II) and PT-141 (Bremelanotide) are both synthetic melanocortin peptides derived from alpha-melanocyte-stimulating hormone (α-MSH), and both activate melanocortin recepto

By Recovery & Performance Peptides Editorial Team

Melanotan 2 vs PT-141: Comparing Melanocortin Research Compounds (UK 2026)

Melanotan 2 (MT-II) and PT-141 (Bremelanotide) are both synthetic melanocortin peptides derived from alpha-melanocyte-stimulating hormone (α-MSH), and both activate melanocortin receptors. However, they differ in receptor selectivity, pharmacological profiles, regulatory status, and intended research applications. Understanding these differences is essential for researchers working in the melanocortin system.

🔗 Related Reading: Melanotan 2 UK Complete Research Guide | PT-141 (Bremelanotide) UK Complete Research Guide

Structural Relationship

Both compounds were developed from the naturally occurring α-MSH sequence at the University of Arizona. α-MSH is a tridecapeptide (13 amino acids) derived from ACTH that activates all five melanocortin receptor subtypes (MC1R–MC5R) with varying affinities.

Melanotan 2 is a cyclic lactam analogue of α-MSH — specifically [Nle4, D-Phe7]-α-MSH with a cyclic structure formed by a lactam bridge between Lys5 and Asp10. This cyclisation improves metabolic stability and receptor binding affinity versus linear α-MSH. MT-II is a non-selective agonist with significant activity at MC1R, MC3R, MC4R, and MC5R.

PT-141 was derived from Melanotan 2 — it is actually a metabolite of MT-II that forms in vivo after MT-II administration. Researchers isolated this metabolite and characterised it as retaining the sexual arousal properties of MT-II with reduced pigmentation activity (lower MC1R engagement). PT-141 is a heptapeptide fragment with modifications to the parent sequence.

Receptor Selectivity: The Key Difference

Melanotan 2 activates all MC subtypes with relatively non-selective agonism. Its most prominent effects are:

MC1R (melanocytes): Potent stimulation of eumelanin production — skin darkening. This is the “tanning” effect and was the original target of Melanotan development.

MC3R/MC4R (CNS): Sexual arousal and appetite suppression effects.

MC5R (exocrine glands): Effects on sebaceous and other exocrine gland secretions.

PT-141 has been developed to preferentially activate MC3R and MC4R while producing less MC1R stimulation. This selectivity profile preserves the central sexual arousal effects while substantially reducing the pigmentation effects — making it a more targeted research tool for studying melanocortin-mediated sexual function without confounding melanogenesis effects.

Pigmentation Effects

MT-II produces substantial skin darkening through MC1R-mediated melanogenesis in melanocytes. This is dose-dependent and persistent — lasting weeks after treatment ends. Freckles and existing moles may darken significantly. In research, this pigmentation effect is both a feature (useful for studying melanogenesis and skin pigmentation biology) and a confounder (when the research question concerns sexual function rather than pigmentation).

PT-141 produces substantially less pigmentation than MT-II due to reduced MC1R activity, allowing the sexual function research angle to be studied with less pigmentation confounding.

Sexual Function Research

Both compounds stimulate sexual arousal through CNS MC3R/MC4R activation — producing downstream dopamine release in the mesolimbic pathway and oxytocin release from hypothalamic neurons. MT-II has been shown in early human studies to produce erections in men (including those with organic erectile dysfunction) through this central mechanism.

PT-141/Bremelanotide was developed as the more targeted clinical candidate and has progressed to FDA approval for hypoactive sexual desire disorder (HSDD) in premenopausal women (as Vyleesi, 2019). For researchers specifically studying melanocortin-mediated sexual function without pigmentation confounding, PT-141 is the more appropriate tool.

For researchers studying the relationship between melanogenesis and sexual arousal — or examining all MC receptor subtypes simultaneously — MT-II’s broader receptor profile is a feature rather than a limitation.

Appetite Suppression Research

MC4R activation in the hypothalamus suppresses food intake — MC4R knockout mice develop severe obesity, and MC4R agonism is one of the most effective pharmacological approaches to appetite suppression in rodent models. Both MT-II and PT-141 produce appetite suppression through this mechanism, though the effect may be more pronounced with MT-II given its less selective MC4R engagement alongside MC3R.

For obesity and appetite regulation research, both compounds are relevant. Researchers should consider whether the pigmentation confound of MT-II is acceptable in their study design.

Safety Considerations for Research

Both compounds can produce nausea (a common side effect of melanocortin receptor activation, related to area postrema stimulation) and transient blood pressure changes. MT-II has been associated with more prominent nausea and with spontaneous erections (in male subjects) at doses used for tanning purposes.

PT-141’s clinical pharmacology data from Phase III trials provides a well-characterised safety reference profile: nausea is the most common side effect (approximately 40% of subjects), with transient blood pressure elevation (mean +6 mmHg systolic at peak) observed and generally mild.

Regulatory Status

PT-141/Bremelanotide is FDA-approved in the US (as Vyleesi) for premenopausal HSDD — giving it regulatory validation as a clinical compound. In the UK, it is not licensed and is supplied as a research compound under RUO designation.

Melanotan 2 has no regulatory approval in any jurisdiction and has been the subject of MHRA warnings in the UK due to some suppliers making medicinal claims. It is available as a research compound under RUO designation from legitimate suppliers.

Summary: Which for Which Research Question?

For pigmentation and melanogenesis research: MT-II is the more appropriate tool, with its strong MC1R activity driving the melanogenic cascade directly.

For sexual function research with minimal pigmentation confound: PT-141 is the more selective choice, with clinical trial data supporting its mechanism and dosing.

For appetite regulation and obesity research: Both compounds are relevant; MT-II’s broader profile may produce larger appetite effects.

For comprehensive MC receptor system research across all five receptor subtypes: MT-II’s non-selective profile makes it the broader research tool.

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Melanotan 2 and PT-141 for melanocortin system research. View UK stock →

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Understanding Insulin Syringe Graduations for Peptide Dosing

Insulin syringes are graduated by volume. Not by peptide mass or International Units for non-insulin compounds. The most common insulin syringe is the 1mL U-100 syringe, which has 100 unit markings across its 1mL barrel. Each 'unit' on a U-100 syringe equals 0.01mL (10 microlitres). This is a volume measurement. What it translates to in peptide dose depends entirely on the concentration you created during reconstitution. If you reconstitute 10mg melanotan-2 with 1mL bacteriostatic water, your final concentration is 10mg/mL. Drawing to the 10-unit mark (0.1mL) delivers 1mg of melanotan-2. Drawing to the 5-unit mark (0.05mL) delivers 0.5mg (500mcg). Each single tick (1 unit = 0.01mL) delivers 100mcg. This is straightforward algebra. But only if you know your starting peptide mass and reconstitution volume with precision. The confusion arises because insulin dosing uses IU as the functional unit, and U-100 syringes are calibrated so that 1 unit on the barrel equals 1 IU of U-100 insulin. That relationship does not transfer to melanotan-2 or any other peptide. Melanotan-2 has no standardised IU conversion. It is dosed by mass (mcg or mg), and the syringe measures volume (mL). Calculating dose requires knowing concentration first. We've seen researchers attempt to dose melanotan-2 by counting 'units' on the syringe without performing reconstitution math. The result is wildly inaccurate dosing. Sometimes 5× the intended dose, sometimes one-fifth. The syringe itself is a precision …
STORAGE

13. Reconstitution, storage and stability

MT-II typical research-grade vial: 10 mg lyophilised powder. Reconstitution: Add 2 mL bacteriostatic water (0.9% benzyl alcohol preserved) → 5 mg/mL Post-reconstitution storage: 2-8°C, use within 30-45 days Protect from light and freezing Lyophilised powder (unreconstituted) stable at −20°C for >2 years MT-II aqueous stability is good owing to the cyclic structure and absence of oxidation-labile residues (Nle replaces Met). Aggregation is not a significant issue at research concentrations.
02

Question drills

Open a question for its connected answer.

01What If I've Already Started MT2 at 500mcg Daily and I'm Over 45?+

Reduce immediately to 200mcg and assess tolerance for 48 hours before considering further escalation. Starting at 500mcg in men over 40 dramatically increases risk of severe nausea, presyncope from blood pressure spikes, and flushing episodes lasting 3–6 hours. You've likely already experienced at least one of these. Continuing at that dose compounds cumulative cardiovascular stress without accelerating melanogenesis meaningfully. The tanning response plateaus at receptor saturation, and you've almost certainly exceeded that threshold. Proper titration from this point requires stepping back, not pushing forward.

SOURCE / realpeptides.co ↗
02What If I Experience Nausea and Flushing After Every Injection — Is That Normal or a Sign to Stop?+

Nausea and flushing are expected pharmacological effects of Melanotan-2 melanogenesis at doses above 0.5 mg, occurring in 60–80% of users within 30–90 minutes post-injection and typically resolving within 2–4 hours. These effects result from MC4R activation in the hypothalamus (nausea, appetite suppression) and peripheral vasodilation driven by nitric oxide release (flushing, facial warmth). They are not indicators of peptide impurity or allergic reaction. They are dose-dependent CNS and vascular responses that diminish with repeated exposure as receptor desensitization occurs. Most individuals report that nausea severity decreases by 40–60% after the first week of consistent dosing, and by week three, only mild transient warmth persists. If nausea is severe enough to cause vomiting or lasts beyond 4 hours, the dose is too high. Reduce by 0.25 mg increments until symptoms are tolerable. Administering Melanotan-2 in the evening 1–2 hours before sleep allows side effects to pass during rest, and taking the injection on an empty stomach reduces nausea severity compared to dosing after meals. Persistent severe side effects beyond two weeks of consistent low-dose administration (0.25–0.5 mg) may indicate heightened MC4R sensitivity and warrant discontinuation.

SOURCE / realpeptides.co ↗
03What If the Lyophilised Cake Is Yellow Instead of White?+

Yellowing indicates oxidative degradation, most commonly from improper storage at temperatures above −20°C or exposure to light during shipping. Methionine and cysteine residues in the peptide sequence are highly susceptible to oxidation, forming sulfoxides and disulfides that alter the peptide's three-dimensional structure and reduce melanocortin receptor binding affinity. Even if the peptide still dissolves normally, oxidized MT-2 exhibits reduced potency. Melanogenesis assays typically show 40–70% loss of activity compared to non-oxidized controls. Request replacement from your supplier and verify their cold chain logistics include insulated packaging with gel packs or dry ice for shipments exceeding 24 hours.

SOURCE / realpeptides.co ↗
04What If My Pigmentation Is Uneven or Blotchy During Week 3?+

This is expected. Melanocyte density varies across body regions. The face, forearms, and shoulders contain 2–3× the melanocytes per square centimetre compared to the torso or inner thighs. Continue current dosing without increase and add controlled UV exposure (10 minutes UVB, 3× weekly) to accelerate keratinocyte turnover in lighter areas. Avoid spot-dosing or applying topical MT-2. Systemic peptide administration is the only evidence-supported method. Blotchy pigmentation normalises by weeks 5–6 as slower-responding areas catch up.

SOURCE / realpeptides.co ↗
05What If I'm Using Melanotan-2 Alongside Other Peptides Like MK-677 or CJC-1295?+

No pharmacokinetic interactions exist between Melanotan-2 and growth hormone secretagogues like MK 677 or CJC1295 Ipamorelin. Melanocortin receptors and ghrelin receptors operate through completely separate signalling cascades. The only overlap is injection site management. Rotate sites to prevent localised lipohypertrophy from repeated subcutaneous administration. If you're stacking multiple peptides, maintain separate reconstitution schedules and labelling to avoid cross-contamination.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Rodent Obesity Model Research

Multiple established rodent obesity models have been used in Melanotan 2 appetite and energy balance research: Diet-induced obesity (DIO) mice/rats: High-fat diet fed C57BL/6J mice develop obesity, hyperinsulinaemia, glucose intolerance and leptin resistance within 8–16 weeks. MT-II effects on food intake, body weight, and metabolic parameters (glucose, insulin, leptin, adiponectin) in DIO models characterise melanocortin system pharmacology under conditions of diet-induced leptin resistance. ob/ob mice: Leptin-deficient genetic model of morbid obesity. MT-II effects in ob/ob mice test the leptin-independence of melanocortin agonist efficacy, as described above. MC3R and MC4R knockout models: Used alongside MT-II pharmacology to dissect receptor-specific contributions to food intake, body weight and thermogenic responses. Melanocortin-specific POMC neuron ablation models: Diphtheria toxin receptor (DTR) or Cre/lox-mediated POMC neuron ablation studies examine the consequences of losing endogenous melanocortin tone, with MT-II rescue experiments used to confirm receptor-level functionality.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles

Melanotan 2 vs PT-141 for Research UK 2026

Melanotan 2 vs PT-141 for Research UK 2026 All peptides discussed in this article are intended strictly for laboratory and preclinical research purposes. They are not licensed medicines and are not approved for human th…

Read article